This work may not be copied, distributed, displayed, published, reproduced, transmitted, modified, posted, sold, licensed, or used for commercial purposes. By downloading this file, you are agreeing to the publisher’s Terms & Conditions.


Maintaining Symptom Control: Review of Ziprasidone Long-Term Efficacy Data

Nina R. Schooler, PhD

Published: December 1, 2003

Article Abstract

Reducing the risk of relapse and maintaining symptom control are core goals in the long-termtreatment of patients with schizophrenia or schizoaffective disorder because symptom control canallow patients and clinicians to focus on functional improvement. The atypical antipsychotic agentshave gained widespread acceptance in this setting because they are at least as effective as the conventionalantipsychotic agents, may offer an advantage in relapse prevention, and offer safety advantages,primarily a reduced liability for movement disorders. However, there are differences among the atypicalagents that may affect both clinician choice and patient adherence to long-term therapy. Ziprasidonehas shown long-term antipsychotic efficacy in comparisons with haloperidol, olanzapine, andrisperidone, as well as efficacy in patients switched from another antipsychotic agent. This review examinessymptom efficacy data for ziprasidone in long-term trials that lasted between 28 and 52 weeks.Antipsychotic medication is the foundation of long-term treatment of schizophrenia. Optimization oftreatment for the individual patient requires consideration of symptom control, prevention of relapse,and possible long-term health consequences. Clinical trial data on ziprasidone’s long-term efficacyprovide a firm basis for selection of this agent.

Some JCP and PCC articles are available in PDF format only. Please click the PDF link at the top of this page to access the full text.

Related Articles

Volume: 64

Quick Links: